Innate Pharma updates pipeline timelines in Q3 2026 report
Innate Pharma reported progress on its Nectin-4 ADC, lacutamab and monalizumab programs alongside a cash position of €96.8 million as of September 30, 2026.
SEC filing
4 stories
Innate Pharma reported progress on its Nectin-4 ADC, lacutamab and monalizumab programs alongside a cash position of €96.8 million as of September 30, 2026.
SEC filing
AstraZeneca delayed the Phase 3 trial's high-level data readout by roughly six months, citing the study's event-driven design.
SEC filing
Cash and financial assets fell to €21.4 million as of June 30, 2026, but the company points to a post-period Sobi deal and share placement to fund operations into 2028.
SEC filing
Sobi partnership closed and TELLOMAK-3 is starting as Innate reports €21.4 million in cash and a runway extended to the end of Q1 2028.
SEC filing (2)